What is the guidance of the clinical value of drugs to guide the development of anti-tumor drugs?

In July this year, China's CDE issued the "Guiding Principles for Clinical Research and Development of Anti-tumor Drugs Oriented by Clinical Value"

The clinical value of new drug development is the most important in the future

After reading the document carefully, I found that the most important point of this guiding principle is to guide the development of anti-tumor drugs with clinical value as the orientation

Therefore, we can predict that in the near future, not only anti-tumor drugs, anti-cardiovascular drugs, but also other types of chronic disease drugs will be defined by this principle in the future

In addition, if the company is in the initial stage of the development of a new drug project, the clinical value of its candidate drug is not high, which will cause it to be difficult to deliver when it is finally approved

So, what is the clinical value of drugs?

Regarding what is the clinical value of drugs, in fact, in general, the clinical value research and selection of drugs in various countries are also diverse and varied

There are other candidate options for the clinical value of drugs

So how to define these six aspects in the research and development of new tumor drugs? In fact, the guidelines are relatively vague, or a bit puzzling

Why has it stimulated the sharp drop in the research and development of various new drugs?

Why did it stimulate the sharp drop in the research and development of various new drugs this time? The first factor is economic considerations

In general, the official launch of this policy by CDE is a preventive agent against the chaos in the tumor drug research and development market